Australian Centre for Sexual Health, Suite 2-4, Berry Road Medical Centre, 1a Berry Road, St Leonards, NSW 2065, Australia.
Expert Opin Pharmacother. 2010 Jul;11(10):1741-52. doi: 10.1517/14656566.2010.493174.
Premature ejaculation (PE) is a common male sexual disorder which is associated with substantial personal and interpersonal negative psychological factors. Drug treatment of PE with an off-label antidepressant selective serotonin reuptake inhibitor (SSRI) drug is common. The lack of an approved drug and total reliance on off-label treatment represents a substantial unmet treatment need.
Medline and the proceedings of major international and regional scientific meetings during the period 1994-2010 were searched for publications or abstracts using the word 'dapoxetine' in the title, abstract or keywords. This search was then manually cross-referenced for all papers. This review encompasses studies of dapoxetine pharmacokinetics, animal studies, human phase I, II and III efficacy and safety studies and drug-interaction studies. Dapoxetine is a potent SSRI, which is administered on demand 1-3 h before planned sexual contact. Dapoxetine is rapidly absorbed and eliminated, resulting in minimal accumulation and has dose-proportional pharmacokinetics, which are unaffected by multiple dosing. Dapoxetine 30 and 60 mg has been evaluated in five randomized, double-blind, placebo-controlled studies in 6,081 men aged > or = 18 years. Outcome measures included stopwatch-measured intravaginal ejaculatory latency time (IELT), Premature Ejaculation Profile (PEP) items, clinical global impression of change (CGIC) in PE, and adverse events. Mean IELT, all PEP items and CGIC improved significantly with both doses of dapoxetine versus placebo (p < 0.001 for all). The most common adverse events included nausea, dizziness and headache, and evaluation of validated rated scales demonstrated no SSRI class-related effects with dapoxetine use.
Readers will gain insight into the epidemiology, pathophysiology and contemporary drug treatment of premature ejaculation.
Dapoxetine, as the first drug developed for PE, is an effective and safe treatment for PE and represents a major advance in sexual medicine.
早泄(PE)是一种常见的男性性障碍,它与大量的个人和人际关系的负面心理因素有关。药物治疗早泄与一个非标签抗抑郁药选择性 5-羟色胺再摄取抑制剂(SSRIs)药物是常见的。缺乏一种批准的药物和完全依赖于非标签治疗代表了一个实质性的未满足的治疗需要。
Medline 和主要国际和地区科学会议的会议记录在 1994 年至 2010 年期间进行了搜索使用的词“达泊西汀”在标题,摘要或关键字。然后,这个搜索手动交叉引用所有的论文。这个审查包括达泊西汀药代动力学研究,动物研究,人体阶段 I、II 和 III 疗效和安全性研究和药物相互作用研究。达泊西汀是一种有效的 SSRI,它在计划的性接触前 1-3 小时按需给药。达泊西汀吸收迅速,消除迅速,导致最小的积累和有剂量比例药代动力学,不受多次给药的影响。达泊西汀 30 和 60 毫克已在五个随机,双盲,安慰剂对照研究中评估在 6081 名年龄大于或等于 18 岁的男性。结局测量包括秒表测量阴道内射精潜伏期时间(IELT),早泄概况(PEP)项目,PE 的临床总体印象的变化(CGIC),和不良事件。平均 IELT,所有 PEP 项目和 CGIC 显著改善与两个剂量的达泊西汀与安慰剂(p < 0.001 为所有)。最常见的不良事件包括恶心,头晕和头痛,和评估验证评定量表表明没有 SSRI 类相关的影响与达泊西汀的使用。
读者将获得洞察力进入流行病学,发病机制和当代药物治疗早泄。
达泊西汀,作为第一个开发的药物治疗早泄,是一种有效的和安全的治疗早泄和代表了一个重大的进展在性医学。